Overall, our findings contribute to the body of literature that demonstrates the utility of tau-PET as an accurate predictor of cognitive trajectories for patients with preclinical Alzheimer’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.